

Risk of Malignancy Index for Preoperative Evaluation of Pediatric Ovarian Tumors

Amos HP Loh¹, Chiou-Li Ong², Shu-
Lin Lam², Joyce HY Chua¹, Chan-Hon
Chui¹

¹ Department of Paediatric Surgery


² Department of Diagnostic and Interventional Imaging

KK Women's and Children's Hospital, Singapore


Introduction

Background and aim

Preop assessment:
Malignant potential?



Surgical decisions:
MIS approach? Ovarian salvage?
Extent of staging?




Compromise oncological management
VS
Unnecessary laparotomies & morbidity



Introduction

Background and aim

- **Aim: develop & validate risk-of-malignancy index for pediatric ovarian tumors**



Existing prediction tools	Novel prediction tool
Adult Obgyn tumors	Childhood tumors
Screen detected	Acute presentation
Increasingly complicated	Based on accessible investigations

mathematical models

Materials & Methods

Scoring index development & validation

Development

Candidate variables



Histological outcome

Training set:

55 masses
(55 girls)



Validation


sensitivity, specificity,
NPV, PPV, LR+, LR-

Testing set:

15 masses
(14 girls)


Materials & Methods

Scoring index development & validation



Materials & Methods

Scoring index development & validation



Materials & Methods

Study cohort: training set

Benign (n=47, 85%)		Non-benign (n=8, 15%)	
Serous cyst	2	Immature teratoma (with/without yolk sac component)	4
Mature teratoma	18	Cystic mucinous tumor with borderline change	2
Mixed seromucinous cystadenoma	1	Endodermal sinus tumor	1
Serous cystadenoma	1	Sex cord tumor with annular tubules	1
Mucinous cystadenoma	1		
Serous cystadenofibroma	1		
Follicular & luteal cysts (intact)	6		
Follicular & luteal cysts (hrr'gic)	8		
Cystic fibrous ovarian tissue	4		

Study cohort: testing set

Benign (n=13, 87%)		Non-benign (n=2, 13%)	
Serous cyst	1	Yolk sac tumor	1
Mature teratoma	1		
Serous cystadenoma	1	Sertoli-Leydig cell tumor	1
Follicular & luteal cysts (intact)	6		
Hemorrhagic / infarcted cysts	2		
Paratubal cyst	1		
Torted fallopian tube	1		



Results

variables

Shortlisted candidate

Variable		Values
Clinical		
Age		(years, less / greater than threshold)
Race		(Chinese / Malay / Indian / Others)
Menarche		(pre / post-menarche)
Presenting symptom	Pain	(absent / present)
	Painless mass	(absent / present)
	Hormonal symptoms	(absent / present)
	Incidental diagnosis on imaging	(absent / present)
Biochemistry	AFP	(ug/L, not raised / raised)
	BHCG	(IU/L, not raised / raised)
	CA125	(U/mL, not raised / raised)
	CEA	(U/mL, not raised / raised)
Imaging (CT or US)		
Max diameter of lesion		(cm, less / greater than threshold)
Max diameter of largest solid component		(cm, less / greater than threshold)
Loculation		(uniloculated / multiloculated or solid)
Septal structure		(<3mm / >3mm or solid lesion)
Enhancement or flow in septum or a solid papillary projection		(enhancement / no enhancement)
Ascites		(absent / present)
Irregular internal cyst wall		(absent / present)
Radiologist's subjective opinion		(benign / indeterminate or malignant)

Results

(training set)

Univariate analysis

Variable		Benign (%)	Non-benign	P
Clinical				
Presenting symptom	Painless mass	14.9	50.0	.042
	Hormonal symptoms	2.1	37.5	.008
Biochemistry	AFP (raised)	12.8	50.0	.029
	BHCG (raised)	2.1	12.5	.272
	CA125 (raised) *	13.2	83.3	.001
	CEA (raised) **	0.0	28.6	.026
Imaging (CT or US)				
Max diameter of lesion (cm) ***		8.20 ± 4.1	23.9 ± 11.9	.007
Max diameter of largest solid component (cm) ***		1.45 ± 2.4	6.0 ± 5.2	.044
Loculation (multiloculated or solid)		14.9	100.0	<.001
Septal structure (>3mm or solid)		21.3	87.5	.001
Enhancement or flow in septum or a solid papillary projection		23.4	37.5	.405
Ascites (present)		8.5	87.5	<.001
Irregular internal cyst wall (present)		4.3	50.0	.018
Radiologist's subjective opinion (indeterminate or malignant)		23.4	37.5	.001

*n=38 benign / 6 non-benign; **n=34 benign / 7 non-benign; ***Data presented as mean ± S.D

Results

Clinical score & Imaging

score

Variable	Coeff. (logO.R .)	S.E. of coeff.	Wald (chi-sq)	O.R. (95% C.I.)	P (2-tail)
Clinical					
Age 12 years and above	3.13	1.33	5.52	22.9 (1.7 - 313.1)	.019
Any elevated tumor marker (AFP/BHCG/CEA/CA125)	3.69	1.32	7.81	39.9 (3.0 - 530.2)	.005
Hormonal symptoms	5.08	1.91	7.12	161.0 (3.9 - 6730.9)	.008
Imaging					
NA (confounding from multicollinearity)					
<div style="border: 1px solid black; padding: 5px; display: inline-block;"> Score developed from ROC curves of significant univariate variables </div>					

Results

Clinical score & Imaging

score

Clinical score:

<i>Variable</i>	<i>Criteria</i>	<i>Points</i>
Age	12 and above	3
Tumor marker (<i>AFP/BHCG/CEA/CA125</i>)	Any raised	4
Hormonal symptoms	Present	5
Total points		

Non-benign outcome = Total points \geq 9

Imaging score (*un-weighted*):

<i>Variable</i>	<i>Criteria</i>	<i>Points</i>
Maximum diameter of lesion, by age	> 70mm (up to 12 years old)	1
	> 150mm (above 12years old)	
Septal thickness	> 3mm or solid lesion	1
Loculation	Multiloculated or solid lesion	1
Internal irregular cyst wall	Present	1
Ascites	Present	1
Radiologist's impression	Indeterminate or malignant	1
Total points		

Non-benign outcome = Total points \geq 4

Results

Clinico-Radiological score

Variable	Coeff. (log O.R .)	S.E. of coeff.	Wald (chi-sq)	O.R. (95% C.I.)	P (2-tail)
Clinico-radiological					
Max diameter of largest solid component	0.85	0.33	6.66	2.3 (1.2 - 4.4)	.010
Enhancement or flow in a septum or solid papillary projection	4.32	2.08	4.32	75.0 (1.3 - 4389)	.038
Hormonal symptoms	6.06	2.69	5.07	428.3 (2.2 - 83469)	.024

Results

Clinico-Radiological score

Clinico-radiological score:

<i>Variable</i>	<i>Criteria</i>	<i>Points</i>
Max diameter of largest solid component	(cm)	(value in cm)
Enhancement / flow in a septum / solid papillary projection	Present	4
Hormonal symptoms	Present	6
Total points		


Non-benign outcome = Total points \geq 7

Results

Comparison of ROC

curves

ROC curves of scoring indices




	Area under ROC curve	S.E.	95% C.I.
Clinico-radiological score	.964	.036	.894 - 1.034
Imaging score	.939	.057	.828 - 1.050
Clinical score	.927	.040	.849 - 1.005

Results

Validation: clinico-

radiological score

Modelled outcomes at cutoff value ≥ 7 points



	NPV (%)	PPV (%)	Specificity (%)	Sensitivity (%)
Training set	97.9	87.5	97.9	87.5
Testing set	100.0	66.7	92.3	100.0

Results

Validation: clinico-

radiological score

Modelled outcomes for total data set at cutoffs:

Cutoff	NPV (%)	PPV (%)	Specificity (%)	Sensitivity (%)	False -ve	False +ve
≥ 5	98.1	50.0	85.0	90.0	1	9
≥ 6	98.1	52.9	86.7	90.0	1	8
≥ 7	98.3	81.8	96.7	90.0	1	2
≥ 8	95.2	87.5	98.3	70.0	3	1
≥ 8	95.2	100.0	100.0	70.0	3	0
≥ 9	93.8	100.0	100.0	60.0	4	0

Results

benign cases

Validation: scores for non-

	Clinico-radiological score (Cutoff: ≥ 7)	Clinical score (Cutoff: ≥ 9)	Imaging score (Cutoff: ≥ 4)
Sex cord tumor with annular tubules	10.0	7.0	1.0
Cystic mucinous tumor, focal borderline change	10.0	13.0	4.0
Yolk sac tumor	7.5	7.0	4.0
Immature teratoma with yolk sac component	17.2	15.0	5.0
Immature teratoma grade 1	11.1	14.0	6.0
Yolk sac tumor (Endodermal sinus tumor)	10.5	14.0	6.0
Immature teratoma grade 2	11.6	14.0	5.0
Immature teratoma grade 1	8.3	14.0	6.0
Borderline mucinous tumor	4.0	8.0	5.0
Sertoli-Leydig cell tumor	7.4	12.0	3.0

Discussion

Clinico-radiological score



<i>Variable</i>	<i>Criteria</i>	<i>Points</i>
Max diameter of largest solid component	(cm)	(value in cm)
Enhancement / flow in a septum / solid papillary projection	Present	4
Hormonal symptoms	Present	6
Total points		

Discussion

Clinico-radiological score: excluded variables



<i>Variable</i>	<i>Criteria</i>	<i>Points</i>
Max diameter of largest solid component	(cm)	(value in cm)
Enhancement / flow in a septum / solid papillary projection	Present	4
Hormonal symptom	Present	6
Total points		

Tumor markers

Discussion

Clinico-radiological score: excluded variables



<i>Variable</i>	<i>Criteria</i>	<i>Points</i>
Max diameter of largest solid component	(cm)	(value in cm)
Enhancement / flow in a septum / solid papillary projection	Present	4
Hormonal symptom	Present	6
Total points		


Tumor markers

Absolute lesional size

Discussion

Study limitations

- ❖ **Small numbers**
- ❖ **Retrospective data**
 - **Limit statistical strength**
 - **Limit number of candidate variables**
 - » ***Opt to include larger number & range of variables***
- ❖ **Established tests / features**
 - **Mostly adult experience**
 - **Exclude lesser-established markers**
 - » ***Pilot index: easily applicable & usable***




Discussion

Future development

❖ Impact on treatment outcomes

- Reduce understaging
- Reduce surgical morbidity

❖ Validate in other populations



Summary

- ❖ **Goal: Objective risk evaluation within limits of current modalities**
- ❖ **Result: Pediatric Risk of Malignancy Index**



<i>Variable</i>	<i>Criteria</i>	<i>Points</i>
Max diameter of largest solid component	(cm)	(value in cm)
Enhancement / flow in a septum / solid papillary projection	Present	4
Hormonal symptoms	Present	6
Total points		

Acknowledgements

- **Singapore Clinical Research Institute**
Pryseley Nkouibert Assam, biostatistician



Questions

